UNITED STATES SECURITIES AND EXCHANGE COMMISSION April 19, 2018

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Kala Pharmaceuticals, Inc.

File No. 001-38150 - CF#36188

Kala Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on April 2, 2018.

Based on representations by Kala Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.18 through October 4, 2027 Exhibit 10.21 through June 27, 2024

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary